





Figure 2








Figure 4



Control



Composition according to the invention

Figure 5




Figure 6a




Figure 6b




Figure 6c




Figure 6d






Figure 6e



Control



Composition according to the invention

Figure 6f




Figure 7a







Figure 7b










Figure 7f






Figure 7g









Figure 8b






Figure 8d




Figure 8e




Figure 9a

Composition according to the invention




Figure 9b

Control




Figure 10




Figure 11a




Figure 11b




Figure 12a




Figure 12b




Figure 13a





Figure 13b






Figure 13d





Figure 14



PPAR alpha target genes upregulated in muscle

(*enrichment by the composition according to the invention versus control)

Fatty acid uptake

*	
CES1	3,49614854
LIPE	3,2040358
MGLL	3,92655389
ABCA1	1,25607476
CD36	2,95181319

Fatty acid mitochondrial oxidation

*	
ACAA2	2,00745053
ACADM	1,67161308
ACADVL	1,5188451
ACAD9	2,94931806
DECR1	2,42895757
HADHB	1,54951208
ACAT2	2,50580403
HADH	1,27745581
HMGCS1	2,84725028
SLC25A1	2,36925891
HIBCH	2,52600452

Fatty acid peroxisomal oxidation

*	
ABCD2	3,31015463
ACOX1	1,48341923
EHHA2H	2,83032541
ALDH3A2	1,30356918
ALDH2	2,16399101
ACAA2	2,00745053
CYP4B1	2,7877106
ALDH1A2	5,05235117
ALDH9A1	2,318474
ALDH1A3	1,62703052

Figure 15

Figure 16

Genes improving muscle trophicity

*	
HRAS	5,32449125
THY1	6,22464916
RASD1	2,38241099
CCDC28B	2,48449424
CCDC98	3,2286061
TRIB2	4,68603955
RASSF8	2,24531139
RASA1	1,28172499
CFDP1	3,96526134
GDF5	1,41929071
MYOG	1,60633561
TUBA3	4,55468017

Genes improving neuro-muscular junction

*	
PKP2	4,13750304
ZNRF2	1,82614626

Genes improving muscle protein synthesis


*	
PDIA6	4,73241446

Genes improving muscle contractility

*	
MYBPH	5,01790252
MYH3	1,77686133
ACTC1	5,76199977

(*enrichment by the composition according to the invention versus control)

A



Total number of screened genes: 44715

B

Pathway name (MSigDB)	Score	Probability
PYRUVATE_METABOLISM	1.16	0.0010
BIOPEPTIDESPATHWAY	0.94	0.0014
SPRYPATHWAY	1.11	0.0014
PK3PATHWAY	0.77	0.0021
LONGEVITYPATHWAY	1.45	0.0022
CITRATE_CYCLE_TCA_CYCLE	1.43	0.0027
INFATPATHWAY	0.64	0.0039
P38MAPKPATHWAY	0.90	0.0043
BUTANOATE_METABOLISM	1.06	0.0049
IGF1PATHWAY	1.03	0.0051
IL6PATHWAY	0.68	0.0051
MGALPAINPATHWAY	0.74	0.0057
PROPANOATE_METABOLISM	1.14	0.0057
PANTOTHENATE_AND_COA_BIOSYNTHESIS	1.13	0.0061
HISTIDINE_METABOLISM	1.29	0.0062
OXIDATIVE_PHOSPHORYLATION	0.53	0.0073
EGF_RECEPTOR_SIGNALING_PATHWAY	0.80	0.0074
FMLPPATHWAY	0.58	0.0075
EGFPATHWAY	0.75	0.0077
MITOCHONDRIA	0.66	0.0077
VALINE_LEUCINE_AND_ISOLEUCINE_DEGRAD.	1.08	0.0080
UBIQUINONE_BIOSYNTHESIS	0.88	0.0082
ARGININE_AND_PROLINE_METABOLISM	0.81	0.0087
HIF1PATHWAY	1.18	0.0093
CERAMIDEPATHWAY	0.70	0.0095
GPCRPATHWAY	0.65	0.0096

Figure 17